发明名称 |
Pharmaceutical combination |
摘要 |
The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. |
申请公布号 |
US2015174126(A1) |
申请公布日期 |
2015.06.25 |
申请号 |
US201514639265 |
申请日期 |
2015.03.05 |
申请人 |
BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
发明人 |
STEFANIC Martin Friedrich;HILBERG Frank;KAISER Rolf;SHAPIRO David |
分类号 |
A61K31/496;A61N5/10;A61K31/519 |
主分类号 |
A61K31/496 |
代理机构 |
|
代理人 |
|
主权项 |
1. Pharmaceutical combination comprising the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof and the compound N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid or a pharmaceutically acceptable salt thereof. |
地址 |
Ingelheim am Rhein DE |